Christopher Yea
Corporate Officer/Principal en KALVISTA PHARMACEUTICALS, INC. .
Fortuna: 839 976 $ al 30/04/2024
Cargos activos de Christopher Yea
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2016 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Corporate Officer/Principal | 01/11/2015 | - |
Historial de carrera de Christopher Yea
Antiguos cargos conocidos de Christopher Yea.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Director de Operaciones | 01/01/2008 | 01/11/2015 |
Fundador | 01/01/2008 | 01/11/2015 |
Formación de Christopher Yea.
University of Bristol | Doctorate Degree |
Estadísticas
Internacional
Reino Unido | 4 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectorial
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Christopher Yea
- Experiencia